Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.

Regeneron is partnering with BARDA to develop a next-generation COVID-19 antibody • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. is aiming to develop a monoclonal antibody for preventing COVID-19 in vulnerable populations that it hopes will be able to overcome the mechanisms of resistance that in the past have quickly rendered promising drugs useless with the emergence of new variants and subvariants of SARS-CoV-2. The firm has made an agreement with the US Biomedical Advanced Research and Development Authority to support its efforts.

Regeneron said 22 August that it entered into the agreement with BARDA to support clinical development, clinical manufacturing and regulatory...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains